UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 188

Sortiert nach

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2023-01, Vol.15, p.17588359231161409-17588359231161409

2023

Link zum Volltext

Verfügbarkeit prüfen

β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers

Journal of neuroimmune pharmacology, 2020-03, Vol.15 (1), p.27-36

2020

Link zum Volltext

Verfügbarkeit prüfen

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Clinical cancer research, 2018-12, Vol.24 (24), p.6195-6203

2018

Link zum Volltext

Verfügbarkeit prüfen

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer

Therapeutic Advances in Medical Oncology, 2021, Vol.13, p.1758835921992976-1758835921992976

2021

Link zum Volltext

Verfügbarkeit prüfen

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma

Journal of thoracic oncology, 2017-05, Vol.12 (5), p.878-883

2017

Link zum Volltext

Verfügbarkeit prüfen

Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC

Journal of thoracic oncology, 2024-02, Vol.19 (2), p.190-192

Le, Xiuning

2024

Link zum Volltext

Verfügbarkeit prüfen

Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer

Nature communications, 2021-11, Vol.12 (1), p.6655-6655, Article 6655

2021

Link zum Volltext

Verfügbarkeit prüfen

MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities

Cancers, 2023-01, Vol.15 (3), p.612

2023

Link zum Volltext

Verfügbarkeit prüfen

Resistance to EGFR Inhibitors: Fitness, Competition, and Diversity

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.390-392

Le, Xiuning

2023

Link zum Volltext

Verfügbarkeit prüfen

Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Current oncology reports, 2020-04, Vol.22 (4), p.31-31, Article 31

2020

Link zum Volltext

Verfügbarkeit prüfen

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

Cancer discovery, 2016-10, Vol.6 (10), p.1134-1147

2016

Link zum Volltext

Verfügbarkeit prüfen

Heterogeneity in MET-Aberrant NSCLC

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.504-506

Le, Xiuning

2021

Link zum Volltext

Verfügbarkeit prüfen

New Actions on Actionable Mutations in Lung Cancers

Cancers, 2023-05, Vol.15 (11), p.2917

2023

Link zum Volltext

Verfügbarkeit prüfen

Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review

International journal of molecular sciences, 2023-04, Vol.24 (9), p.7781

2023

Link zum Volltext

Verfügbarkeit prüfen

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

Oncogene, 2020-02, Vol.39 (9), p.1846-1859

2020

Link zum Volltext

Verfügbarkeit prüfen

Antibody-drug conjugates in lung cancer: dawn of a new era?

NPJ precision oncology, 2023-01, Vol.7 (1), p.5-5, Article 5

2023

Link zum Volltext

Verfügbarkeit prüfen

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET -amplified NSCLC and first-line osimertinib resistance

Future oncology (London, England), 2022-03, Vol.18 (9), p.1039

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of RAS on the genesis of embryonal rhabdomyosarcoma

Genes & development, 2007-06, Vol.21 (11), p.1382-1395

2007

Link zum Volltext

Verfügbarkeit prüfen

AI in drug discovery and its clinical relevance

Heliyon, 2023-07, Vol.9 (7), p.e17575-e17575, Article e17575

2023

Link zum Volltext

Verfügbarkeit prüfen

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9514-9514

2020

Link zum Volltext

Verfügbarkeit prüfen

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR -Mutant Non-Small Cell Lung Cancer

Cancers, 2022-12, Vol.14 (24), p.6127

2022

Link zum Volltext

Verfügbarkeit prüfen

Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening

Cancer medicine (Malden, MA), 2024-03, Vol.13 (5), p.e7069-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

Frontiers in oncology, 2024-03, Vol.14, p.1324057

2024

Link zum Volltext

Verfügbarkeit prüfen

Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish

Proceedings of the National Academy of Sciences - PNAS, 2007-05, Vol.104 (22), p.9410-9415

2007

Link zum Volltext

Verfügbarkeit prüfen

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group

Journal of thoracic disease, 2018-07, Vol.10 (7), p.3909-3921

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(179)

Publikationsform

Artikel
(187)
Berichte
(1)

Sprache

Englisch
(187)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(90)
Life Sciences & Biomedicine
(85)
Oncology
(72)
Humans
(64)
Lung Neoplasms - Drug Therapy
(40)
Mutation
(40)
Lung Neoplasms - Genetics
(38)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(36)
Carcinoma, Non-Small-Cell Lung - Genetics
(34)
Lung Cancer
(26)
Respiratory System
(21)
Erbb Receptors - Genetics
(20)
Immunotherapy
(19)
Lung Neoplasms - Pathology
(18)
Carcinoma, Non-Small-Cell Lung - Pathology
(17)
Female
(17)
Male
(16)
Non-Small Cell Lung Carcinoma
(16)
Protein Kinase Inhibitors - Therapeutic Use
(15)
Cancer
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer

β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma

Partners in Crime: Co-Occurring Genetic Alterations in EGFR-Mutant NSCLC

Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer

MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities

Resistance to EGFR Inhibitors: Fitness, Competition, and Diversity

Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

Heterogeneity in MET-Aberrant NSCLC

New Actions on Actionable Mutations in Lung Cancers

Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

Antibody-drug conjugates in lung cancer: dawn of a new era?

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET -amplified NSCLC and first-line osimertinib resistance

Effects of RAS on the genesis of embryonal rhabdomyosarcoma

AI in drug discovery and its clinical relevance

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR -Mutant Non-Small Cell Lung Cancer

Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening

Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features

Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group

Suchergebnisse filtern